Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BioCardia, Inc.

Get SEC filing alerts via email and in your feed for BioCardia, Inc.

BCDA BCDAW

BioCardia, Inc.

About BioCardia, Inc.

BioCardia, Inc. is a clinical-stage biotechnology company developing autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases, including ischemic heart failure, chronic myocardial ischemia, and acute respiratory distress syndrome. Its core products include the CardiAMP autologous cell therapy system and CardiALLO allogeneic mesenchymal stem cell therapies, delivered via the proprietary Helix biotherapeutic delivery platform. BioCardia targets specialist cardiologists and medical centers, leveraging patented technologies and a direct sales model.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BioCardia, Inc.

1
1
BioCardia, Inc. BioCardia Reports $2.3 Million Net Loss in Q1 2026, Plans to Raise Additional Capital

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
BioCardia, Inc. BioCardia Reports $8.2 Million Net Loss and Zero Revenue for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
BioCardia, Inc. BioCardia Reports Q3 2025 Financial Results with $1.5 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BioCardia, Inc. BioCardia Reports Revenue Decline and Increased Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BioCardia, Inc. BioCardia Reports Decline in Revenue and Increased Net Losses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BioCardia, Inc. BioCardia Reports $7.9 Million Net Loss and $58,000 Revenue for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
BioCardia, Inc. BioCardia Reports Improved Liquidity, Reduced Losses, and Capital Raising Efforts in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments